Search

Feb 26, 2024
Pravin Dugel on taking the job of executive chairman at Ocular Therapeutix
He describes what made him excited about the company, and why he views diabetic retinopathy as potentially a bigger opportunity than wet AMD

Jun 12, 2023
OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO
Ocular Therapeutix CEO Antony Mattessich describes the 12-month data his company has reported for its extended release TKI for wet AMD.